AbbVie (ABBV) Acquisitions (2012 - 2025)

AbbVie (ABBV) has reported Acquisitions for 10 consecutive years, with $204.0 million the latest figure, recorded in Q1 2025.

• On a quarterly basis, Acquisitions fell 97.78% year-over-year to $204.0 million in Q1 2025; TTM through Dec 2025 was $204.0 million, a 98.83% decrease from a year earlier, with the FY2025 full-year figure at $204.0 million, down 98.83% from the prior year.
• Acquisitions was $204.0 million for Q1 2025 at AbbVie, down from $8.3 billion in the prior quarter.
• Over five years, Acquisitions peaked at $9.2 billion in Q1 2024 and troughed at $204.0 million in Q1 2025.
• A 3-year average of $4.6 billion and a median of $4.4 billion in 2021 frame the typical range for Acquisitions.
• Across the five-year window, Acquisitions jumped 330.33% in 2021 and slumped 97.78% in 2025, its largest moves.
• Over 3 years, Acquisitions stood at $525.0 million in 2021, then jumped by 1479.81% to $8.3 billion in 2024, then slumped by 97.54% to $204.0 million in 2025.
• The last three Acquisitions figures came in at $204.0 million (Q1 2025), $8.3 billion (Q3 2024), and $9.2 billion (Q1 2024), per Business Quant data.